Search Results

You are looking at 1 - 10 of 71 items for :

  • "chemotherapy administration" x
  • All content x
Clear All
Full access

Sujana Movva, Margaret von Mehren, Eric A. Ross, and Elizabeth Handorf

-up. We constructed survival curves using Kaplan-Meier methods, testing for significance with the log-rank test. We examined the association between chemotherapy administration and survival using propensity score methods. 6 In large, observational data

Full access

Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

study evaluated the factors associated with chemotherapy administration in patients with stage III colon cancer in a population-based study from Germany, in which both patient and hospital characteristics were ascertained in great detail. Methods Study

Full access

Robert C. Stillman and Emily Konerman

Background: The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solve Research Institute is a 356-bed cancer care hospital that is part of The Ohio State University Medical Center. In addition to the inpatient beds, the hospital services 175 ambulatory infusion chairs. Each month, we administer over 6,000 chemotherapy infusions on an IV pump. Smart IV pumps in tandem with hospital information technology infrastructure integrate IV drug administration pump data with the electronic medical record (EMR) and computerized physician order entry to decrease risk of error and increase patient safety. The closed loop system transmits the medication infusion rate and the prescribed dose to the smart pump to deliver the medication. The smart pump in turn transmits the dose and volume delivered to the EMR to accurately capture what the patient received. The ability to wirelessly transmit clinical information from the EMR to automatically program the IV pump with specific data was implemented in March 2018 as part of a system-wide safety initiative to enhance patient safety via the reduction of error during medication administration. Methods: IV pump integration has been in use since March 2018; the organization has robust data on the use of smart pump technology that allowed for comparison of data pre- and postimplementation of pump integration. This includes: total suite usage, count of basic infusions, severe harm averted, total good catches, and event-reporting data. Post-integration, the overall compliance of utilizing pump integration (sending an order from the EMR to the smart IV pump) is also continuously monitored. Results: The implementation of pump interoperability resulted in a safer delivery of infused medications (). The use of “basic Infusion” or unprotected infusion function decreased while our use of the appropriate safeguarded pump program increased. The compliance at the medical center increased from about 86% to almost 94%. With increased usage of the pump interoperability, the potential for severe harm as well as human programming errors decreased significantly. Conclusion: The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solve Research Institute is able to deliver infused medications via a smart pump in a safer, more automated system with the implementation of pump integration. We are able to reduce the “human factor” in medication delivery by reducing keystrokes and opportunities for manual programming errors. Pre-integration data cannot be isolated for the cancer hospital only, from our post-implementation data we can infer that our chemotherapy infusions are subsequently safer for our patients.

Full access

Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani

). There was no statistically significant interaction between age and bevacizumab use. Figure 2. Kaplan-Meier survival curve for patients with metastatic nonsquamous non–small cell lung cancer in the national cohort by first-line chemotherapy administration

Full access

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

-Meier estimates of survival following transarterial chemoembolization (TACE). Survival estimates for patients with documented chemotherapy administration at time of TACE procedure for (A) the entire cohort (n=577) by tumor extent, (B) single tumors without

Full access

Saul N. Weingart, Elizabeth Brown, Peter B. Bach, Kirby Eng, Shirley A. Johnson, Timothy M. Kuzel, Terry S. Langbaum, R. Donald Leedy, Raymond J. Muller, Lee N. Newcomer, Susan O’Brien, Denise Reinke, Mark Rubino, Leonard Saltz, and Ronald S. Walters

Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy. (JNCCN 2008;6[Suppl 3]:S1–S14)

Full access

Jeremy Lund, Angela Pearson, and Georgia Keriazes

to identify readmission risk factors after inpatient chemotherapy administration in a tertiary referral center in a comprehensive cancer population. Methods Institution Information Lakeland Regional Health (LRH) is an 851-bed tertiary

Full access

Jamie Chin, Abhinav Rohatgi, and Alexander Hindenburg

performed a QI project to improve clinical care. An average of 10 hours from admission to chemotherapy administration lead to patient dissatisfaction and increased LOS. We sought to improve inefficiencies in our process and reduce the time from admission to

Full access

Eric Roeland, Charles Loprinzi, Timothy J. Moynihan, Thomas J. Smith, and Jennifer Temel

and does not improve survival. 14 A recently conducted prospective, randomized, single-institution clinical trial provides important insight into the question of prolonged chemotherapy administration in patients with incurable NSCLC. 15 In this

Full access

Robert J. Morgan Jr.

states that “All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IP [intraperitoneal] and IV [intravenous] chemotherapy administration before surgery.” Furthermore, the principles of